Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
CEO： Dr. Benjamin J. Zeskind, PhD
Listing Date： 07/30/2021